Objective. Effective treatments for insomnia exist, but few physicians treating headaches have routine methods for screening for insomnia. We sought to 1) describe the migraine characteristics and comorbid conditions that can affect sleep and 2) assess their relationships with positive screens on the Insomnia Severity Index (ISI).
Methods. This is a retrospective cross-sectional study of the migraine and sleep characteristics of new patients in our headache center (August 15, 2015-October 28, 2015) who were suspected of having migraines based on the new patient intake questionnaire. The questionnaire included the ISI, questions about headache characteristics, and screens for psychiatric comorbidities. Two tailed t tests and analysis of variance evaluated relationships between headache characteristics, comorbidities, and ISI score.
Results. A total of 61 new patients were suspected to have migraines. The mean number of headache days per month was 11.6. Only 41% of patients reported sleeping seven or more hours; 49.2% had an ISI of 15 or higher (positive screen). Regarding the insomnia scores, there were no differences between moderate and severe headache pain, between episodic and chronic headaches, and between the associated symptoms (nausea/vomiting, photophobia, phonophobia; P > 0.05). Musculoskeletal pain (18.7 vs 13.8, P 5 0.027), depression (rho 5 0.610), and general anxiety (rho 5 0.436) were associated with higher ISI scores.
Conclusions. Nearly half of the patients with suspected migraines in a headache center screened positive for insomnia, independent of whether they had episodic or chronic headaches. This would generate a substantial number of cognitive behavioral therapy for insomnia (CBT-I) referrals. Given the strong association between comorbid musculoskeletal pain, depression, anxiety, and insomnia, we suggest prioritizing CBT-I referral for those patients regardless of their headache frequency.
Introduction
Migraine patients have a higher prevalence and severity of sleep disorders such as insomnia than patients without migraines [1, 2] . Sleep disturbances may lower the migraine threshold, trigger migraines, contribute to migraine chronification, and expand health care utilization [2] [3] [4] . Sleep disorders are more prevalent in patients with chronic migraines than with episodic migraines [3] . However, episodic migraines have demonstrated associations with insomnia; further, adequate sleep may contribute to lower likelihood of migraine occurrence [5] .
Despite the prevalence and impact of sleep disturbances on migraine severity, frequency, and health care utilization, few headache centers have routine methods for screening for insomnia [4, 6] . Insomnia is the most common sleep disturbance in migraine patients and is amenable to treatment; therefore screening for insomnia may be particularly useful [2] . Cognitive behavioral therapy for insomnia (CBT-I) is considered firstline treatment for primary insomnia [7] [8] [9] . It has similar short-term effects, but longerlasting effects on insomnia than pharmacologic treatments [8] . CBT-I is also effective in insomnia comorbid with psychiatric and medical conditions [10, 11] . Further, recent evidence suggests that behavioral sleep treatments such as CBT-I may improve both sleep and migraine outcomes in people with migraines [12, 13] . However, access to CBT-I may be limited as CBT-I is typically offered primarily at specialized centers [9] . Studies show that even in these specialized centers, physicians across various specialties rarely refer for CBT-I [6] .
Recent studies have shown that CBT-I can be effective when delivered electronically [14] [15] [16] [17] . The availability of these easily disseminated treatment options for insomnia increases the necessity to understand insomnia as a presenting concern in tertiary care headache centers. There are no guidelines available to date on which migraine patients with comorbid insomnia would benefit from referral for CBT-I. Referring all migraine patients with comorbid insomnia for CBT-I might be inappropriate and too burdensome.
Hence, given the underutilization of CBT-I, the purpose of this study was to characterize typical patients presenting for care at a headache center with suspected migraines who may be appropriate to refer for CBT-I [6] . Appropriate CBT-I candidates benefit most from CBT-I [18] . However, screening all patients who present at a headache center for insomnia may be burdensome. Identification of the characteristics that might prompt screening for insomnia in a headache center will lessen this burden. Therefore, this study sought to 1) characterize the insomnia severity of a sample of typical patients presenting for treatment of suspected migraines at a headache center and 2) assess the relationship of migraine characteristics and comorbid conditions with the Insomnia Severity Index (ISI).
Methods

Participants
This is a retrospective cross-sectional study of the headache and sleep characteristics of consecutive new headache patients who presented to the New York University Langone Medical Center Headache Center from August 15, 2015 , to October 28, 2015 , who completed the new patient intake questionnaire, and were suspected of having migraines based on the new patient intake questionnaire. This was a pragmatic study based on patient self-reported symptoms in patients presenting to a Headache Center with headaches with migrainous features. Thus, even though the International Classification of Headache Disorder (ICHD)-3 beta criteria were not used to determine migraine diagnosis, most patients likely had migraine or probable migraine. The new patient intake questionnaire includes questions about patients' headache characteristics (duration, severity, frequency, associated symptoms) and other factors influencing their headaches. There is a headache review of systems (ROS) that included a question regarding sleep duration ("On average, how many hours of sleep do you get a night?"), and there was a list of psychiatric comorbidities ("anxiety, depression, obsessive compulsive disorder, ADHD, learning disability, bipolar disorder, post-traumatic stress disorder, schizophrenia"), which patients were asked to circle if they had been previously diagnosed with one or more of them. In addition, the new patient intake questionnaire included a general review of systems that asked about musculoskeletal pain ("Do you currently have spine pain, join pain, or muscle cramps?"). Our new patient intake questionnaire also includes the Patient Health Questionnaire 9 (PHQ-9), the Generalized Anxiety Disorder 7 (GAD-7), and the Insomnia Severity Index. Thus, all responses on the new patient intake questionnaire are based on patient self-report.
In addition, participants had to be English-speaking adults age 18 years or older who presented to our headache center for the first time. The headache specialist did a preliminary review of the questionnaires and selected the questionnaires of patients with suspected migraine. Suspected migraine was defined as meeting the definition of migraine or probable migraine or meeting all of the criteria for migraine except fewer than five attacks. The data was stored using REDCap Software, version 6.10.14 [19] . The New York University School of Medicine Institutional Review Board approved the study.
Measures
Patient Health Questionnaire 9
The Patient Health Questionnaire 9 is a validated measure of depression severity [20] . It contains nine items, with each response ranked from 0 (not at all) to 3 (nearly every day) [20] . It has excellent reliability (Cronbach's a ¼ 0.89, 16). A PHQ-9 of 0 to 4 indicates minimal depression, of 5 to 9 indicates mild depression, of 10 to 14 indicates moderate depression, of 15 to 19 indicates moderately severe depression, and of 20þ indicates severe depression [20] . A PHQ-9 score of 10 or higher has a sensitivity of 88% and a specificity of 88% for depression [20] . The PHQ-9 of 10 is the recommended cutoff point at which screened patients should be referred to a physician for management of depression and represents an equivalent to the diagnostic algorithm of depression [21] .
Generalized Anxiety Disorder 7
The Generalized Anxiety Disorder 7 is a validated screening tool and measure of severity of generalized anxiety disorder [22] . It is also used for post-traumatic stress disorder, panic disorder, and social anxiety disorder [23] . The GAD-7 contains seven items, with each response ranked from 0 (not at all sure) to 3 (nearly every day) [23] . It has excellent reliability (Cronbach a ¼ 0.92, 19) . A GAD-7 of 0 to 4 indicates minimal anxiety, of 5 to 9 indicates mild anxiety, 10 to 14 indicates moderate anxiety, and of 15þ indicates severe anxiety [23] .
Insomnia Severity Index
The Insomnia Severity Index (ISI) is a validated screening tool and treatment outcome measure for insomnia [24, 25] . It contains seven items, with each response ranked from 0 (not at all) to 4 (very severe) [24] . It has good reliability (Cronbach a ¼ 0.76) [24] . An ISI of 0 to 7 indicates no clinically significant insomnia, of 8 to 14 indicates subthreshold insomnia, and of 15þ indicates clinical insomnia [25] .
Statistical Analyses
We decided to use the National Sleep Foundation (NSF) recommendations to create cutoffs for sleep duration. The recommendations state that adults need at least seven hours of sleep each night though at least six hours of sleep each night might still be appropriate [26] . Thus, we created three NSF categories: 1) met NSF sleep duration recommendation (at least seven hours per night), 2) slept less than recommended but maybe still appropriate hours of sleep (range of six to just under seven hours of sleep), and 3) did not meet NSF sleep duration recommendation.
Our predictors were headache pain severity and frequency, associated symptoms (nausea, vomiting, photophobia, phonophobia), musculoskeletal pain, and PHQ-9 and GAD-7 scores. Two-tailed t tests and analysis of variance (ANOVA) were used to evaluate the relationships between our predictors and the ISI score. Analysis of primary outcome variable normality and Spearman rank were conducted with SPSS version 9.6; t tests and ANOVA were performed with Excel 2013, and alpha set at 0.05. The missing data were handled with pairwise deletion. The only missing data were headache frequency, PHQ-9, and GAD-7 for two participants, headache frequency and GAD-7 for one participant, and headache frequency only for two other participants. There were no other missing data including for the other characteristics, musculoskeletal pain, sleep duration, or ISI score.
Results
Baseline Characteristics
Of the 78 new patients who completed the questionnaire, 61 were suspected of having migraine headaches based on the initial questionnaire (headache lasting four to 72 hours, with at least two out of four migraine characteristics [unilateral, pulsating, moderate-severe pain, interfering with routine physical activity] and associated with at least one of the migraine symptoms [nausea, vomiting, phonophobia, or photophobia]) and hence were included in our study. Table 1 shows the baseline characteristics of our 61 study participants. Of these 61 patients, 75.4% were women. The mean age was 41.5 years old, the mean headache frequency was 11.6 days per month (range ¼ 0 to every day of the month, SD ¼ 9.6), and the median headache frequency was 9.5 days per month. More than one-third (39%) of our participants also had musculoskeletal pain.
Sleep of Headache Center Patients
The average ISI score was 15.2 (SD ¼ 7.767), which falls in the clinical insomnia (moderate severity) category. Figure 1 shows the daily hours of sleep for the patients according to the National Sleep Foundation Recommendations. Only 41% of patients slept the daily sleep duration recommended by the National Sleep Foundation for their ages [26] . About three in five patients (59%) slept less than the recommended sleep duration. However, 69% of patients are either in the "recommended" or in the "maybe appropriate" sleep duration zones. Figure 2 shows the number of hours spent in bed not being able to sleep for the patients. About one-fourth (27.3%) of patients spent at least two hours per night in bed being unable to sleep. Approximately half of the patients (49.2%) screened positive for clinical insomnia (ISI 15). 
ISI Scores for the Headache Characteristics and Comorbidities
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the 61 patients, 34 (55.7%) had associated nausea/vomiting, 42 (68.9%) had photophobia, and 41 (67.2%) had phonophobia. There were no statistically significant differences in ISI scores between moderate (4-6/10) and severe headache pain (7-10/10), between episodic (<15 days per month) and chronic headache (15 days per month), and between the associated symptoms (nausea/ vomiting, photophobia, phonophobia) (P > 0.05).
Among the 61 patients with suspected migraines, 44 (72%) suffered from comorbid musculoskeletal pain (back pain, arthralgias, and/or muscle cramps). The patients who self-reported comorbid musculoskeletal pain on the ROS had significantly higher ISI scores than the patients who did not self-report comorbid musculoskeletal pain on the ROS (13.8 vs 18.7, P ¼ 0.027). Moreover, the patients with comorbid musculoskeletal pain had a mean ISI score that met criteria for clinical insomnia whereas the patients without comorbid pain had a mean ISI that did not meet criteria for clinical insomnia.
Among the 59 patients who completed the PHQ-9 questionnaire, 10 (17%) screened positive for depression. Among the 58 patients who filled the GAD-7 questionnaire, 25 (43.1%) had a GAD-7 of at least 5. The Spearman's correlation between PHQ-9 score and ISI score was strong (rho ¼ 0.610) (Figure 3 ). The Spearman's correlation between GAD-7 and ISI score was moderate (rho ¼ 0.436) (Figure 4 ).
Discussion
In this observational study of patients with suspected migraines in a headache center, there were several key findings: 1) within the overall group of patients, approximately half screened positive for clinically significant insomnia and 59% reported sleeping less than the daily recommended amount; 2) comorbid musculoskeletal pain and psychiatric comorbidity are associated with migraine patients' insomnia scores; 3) ISI scores are not associated with headache characteristics such as headache frequency.
Our results support previous research, which suggests that insomnia is prevalent in migraine patients [1] [2] [3] . Half of our patients screened positive for insomnia (ISI 15), 
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which is much higher than the rates observed in the general population (6% when DSM-IV criteria for insomnia were used) and in primary care clinic patients (the mean ISI score of 410 primary care patients from six different clinics was 8.27 [SD ¼ 6.44]-about half of the mean ISI of our sample) [27, 28] . However, migraine patients are not routinely screened for insomnia. These results support routine screening of migraine patients for insomnia. Screening for insomnia is particularly relevant now that electronic CBT-I interventions are available, and it can easily be disseminated in headache centers. Interestingly, we found an association between self-reported hours of sleep per night categorized according to the NSF guidelines and the ISI scores in our patient population. Thus, out of concern for workflow efficiency, only the patients sleeping less than the duration recommended by the NSF might be asked to fill out the ISI score questionnaire. Figure 5 illustrates a potential screening and referral workflow.
Given the substantial number of migraine patients suffering from insomnia, it is necessary to target those who would benefit from eCBT-I. Morever, CBT-I works best for patients who were appropriately referred [18] . For example, discussing sleep hygiene and prescribing melatonin for a migraine patient with mild insomnia and no comorbid musculoskeletal pain, depression, or anxiety might be enough. We aimed to evaluate potential associations between migraine characteristics and comorbidities on the one hand and insomnia on the other hand to define the target characteristics of migraine patients who would benefit most from CBT-I referral. In our study, musculoskeletal pain and psychiatric comorbidities (depression and anxiety) were associated with ISI scores, which suggests that migraine patients with these comorbidities might benefit most from CBT-I referral, regardless of migraine characteristics. These conditions are all related [29] . CBT-I was found to be effective in insomnia with comorbid depression, anxiety, and/or pain and is thought to be effective in migraine too.
In prior literature, CBT-I was evaluated for patients with chronic migraine [12, 13] . In our study, ISI scores were not associated with headache frequency, severity, or associated symptoms. Hence, we do not think that migraine characteristics should play a role in targeting the headache center patients with migraine to be referred for CBT-I. Our results differ from a recent Korean population-based study that showed that headache frequency and intensity were associated with ISI scores [30] . In their study, the prevalence of migraine was 5.3% and the prevalence of insomnia was 3.6%. Only 9.1% of the migraine patients and 8.2% of the probable migraine patients had a positive screen for insomnia on the ISI using a cutoff score of 15.5. Yet, in our study of headache center patients, nearly half (49.2%) screened positive for insomnia on the ISI. These differences are likely due to the differences expected when conducting crosssectional-based vs headache center-based studies.
Future Work
Comorbid depression, anxiety, and musculoskeletal pain are associated with higher ISI scores in our sample of patients with suspected migraines. CBT-I was found to be effective in patients with comorbid chronic pain disorders, depression, and post-traumatic stress disorder [31] [32] [33] [34] .
Despite the paucity of data on CBT-I for patients with comorbid GAD, a meta-analysis suggested that CBT-I was beneficial for anxiety symptoms, and another study suggested that sequential anxiety-targeted treatment followed by insomnia-targeted treatment provided the most benefit for patients with comorbid insomnia and GAD [34, 35] . However, there are no studies evaluating CBT-I
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If ISI posiƟve and/or at least two iniƟal screens posiƟve, consider eCBT-I referral for migraine patients with comorbid depression, anxiety, and/or chronic pain suffering from insomnia. Such research would be of great interest as prior studies suggested that insomnia management might reduce migraine frequency and sometimes even revert chronic migraines to episodic migraines [12, 13] . A prospective study evaluating the CBT-I referral process of migraine patients with comorbid chronic pain, anxiety, and/or depression who screen positive for insomnia and the efficacy of CBT-I on their migraine frequency, severity, and insomnia is needed.
As chronic pain, depression, and anxiety are known migraine comorbidities and are associated with sleep disturbances, further studies should also adjust for chronic pain, depression, and anxiety when assessing the relationship between migraine and insomnia. In addition, future work needs to focus on the dissemination of CBT-I in forms that can be used across large populations given the large number of people with insomnia. There are electronic versions of CBT-I that might prove beneficial to these patients [17, 36, 37] .
Limitations
This is a retrospective study of patients with suspected migraines based on their new patient intake questionnaire answers who were not formally diagnosed with ICHD-3B criteria. However, given the meticulousness of the questionnaire, we expect most patients to be ultimately diagnosed with migraines. Of note, in a small analysis of 13 migraine patients and 31 probable migraine patients with insomnia, migraine patients had the same prevalence but higher severity of insomnia (estimated by the ISI score) compared with probable migraine patients [30] . Those results do not weaken our study as 1) most patients are expected to be diagnosed with migraine and 2) our study evaluates the initial headache patient questionnaire screening method for insomnia to help facilitate a process for CBT-I referral. The self-reported nature of a questionnaire is associated with biases such as response bias and recall bias as data about headache characteristics and sleep were not collected prospectively. In addition, the sample was taken from a headache center, so our sample differs from the general population, and our patients' symptoms might be worse than in the general population of migraine patients as not all migraine patients are referred to headache specialists. Given than only 10 of our patients had a GAD-7 of more than 10 and the GAD-7 average of all our patients was 4.83, a positive screen for anxiety was not prevalent in our sample. We used the ISI as a screen for insomnia, but we did not use diagnosis of clinical primary insomnia. Finally, there were minimal missing data; therefore, we removed participants casewise for relevant analyses.
Conclusion
The majority of headache center patients sleep less than the recommended duration, and nearly half have clinically significant insomnia, which makes insomnia the most common sleep disturbance in our sample. These results stress the importance of routinely screening migraine patients for insomnia. Given the substantial number of migraine patients with comorbid insomnia, migraine characteristics and comorbidities were evaluated to define a target group of migraine patients who would benefit most from CBT-I referral. We found that migraine patients with comorbid depression, anxiety, and/or musculoskeletal pain have worse insomnia and should be considered for CBT-I referral regardless of headache frequency.
